Market News AIOpen the app

Pyxis Oncology shared new Phase 1 results for micvotabart pelidotin, showing a 39% response rate in head and neck cancer patients.

TrialRead the original at globenewswire.com
Good for PYXS

Pyxis reported a 39% confirmed response rate, and safety remained manageable, supporting a move to Phase 3. These are still Phase 1 findings, and the next trial is not expected to start until mid-2027.

PYXS · Pyxis Oncology

AI read · Good for PYXS

The AI's read

The findings give Pyxis a basis to test MICVO in a later-stage study. Manageable safety adds support, but the results are still from Phase 1. The next study is expected to start in mid-2027, and its results are not yet known.

Get alerts for PYXS

Follow Pyxis Oncology (PYXS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PYXS
Free on the App Store and Google Play, or on the web.